New York biotech scores win as Fed Circ upholds preliminary injunction against Celltrion's biosimilar launch | Ruling follows ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of ...

Wen is among the 40 finalists heading to Washington D.C. Thursday to present their projects to panels of experts. The winners ...

Mutual of America Capital Management LLC reduced its stake in Regeneron Pharmaceuticals by 3.4%, selling 457 shares in Q4.

The Federal Circuit upheld a preliminary injunction blocking the launch of a Celltrion Inc. biosimilar version to Regeneron ...

On Feb. 18, 2025, the U.S. Court of Appeals for the First Circuit adopted the “but for” causality standard for violations of the federal ...

On February 18, 2025, in United States v. Regeneron Pharmaceuticals, the First Circuit held that to establish civil liability under the False ...

In a small study in a community oncology practice, more than 60% of patients with advanced squamous cell skin cancer treated ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

NEW YORK CITY, NY / ACCESS Newswire / March 5, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Biologic treatment for atopic dermatitis appeared to improve growth trajectories for younger children, a trial analysis ...